Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology;Zastosowanie selektywnych modulatorów receptora progesteronowego w leczeniu miȩsniaków macicy oraz ich przyszlłość w ginekologii

Ginekologia Polska

Volumn 84, Issue 9, 2013, Pages 794-800

  Bra̧zert, Maciej ^a   Korman, Marcin P ^a   Pawelczyk, Leszek A ^a  

^a Marcinkowskiego w Poznaniu   (Poland)

Author keywords

Contraception; Selective progesterone receptor modulators; SPRM; Uterine leiomyoma

Indexed keywords

EID: 84888381206     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/1642     Document Type: Article

References (74)

1. Baird D, Dunson D, Cousins D, [et al.]. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003, 188, 100-107.
2. Zimmermann A, Bernuit D, Gerlinger C, [et al.]. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012, 12, 6.
3. Marshall L, Spiegelman D, Goldman M, [et al.]. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998, 70, 432-439.
4. Vikhlyaeva E, Khodzhaeva Z, Fantschenko N. Familial predisposition to uterine leiomyomas. Int J Gynaecol Obstet. 1995, 51, 127-131.
5. Shikora S, Niloff J, Bistrian B, [et al.]. Relationship between obesity and uterine leiomyomata. Nutrition. 1991, 7, 251-255.
6. Ryan G, Syrop C, Van Voorhis B. Role, epidemiology, and natural history of benign uterine mass lesions. Clin Obstet Gynecol. 2005, 48, 312-324.
7. Lippman S, Warner M, Samuels S, [et al.]. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril. 2003, 80, 1488-1494.
8. Catherino W, Parrot E, Segars J. Proceedings from the National Institute of Child Health and Human Development conference on the Uterine Fibroid Research Update Workshop. Fertil Steril. 2011, 95, 9-12.
9. Ishikawa H, Ishi K, Serna V, [et al.]. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010, 151, 2433-2442.
10. Pietura R, Kotarski J, Janczarek M, [et al.]. Uterine artery embolization as a treatment of uterine leiomyomas. Ginekol Pol. 2003, 74, 79-84.
11. Levy B. Modern management of uterine fibroids. Acta Obstet Gynecol Scand. 2008, 87, 812- 823.
12. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001, 2: CD000547
13. Donnez J, Tatarczuk T, Bouchard P, [et al.]. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Eng J Med. 2012, 366, 409-420.
14. Donnez J, Tomaszewski J, Vazquez F, [et al.]. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Eng J Med. 2012, 366, 421-432.
15. Bouchard P, Chabert-Buffet N, Fauser B. Selective progesterone receptor modulators in reproductive medicine : pharmacology, clinical efficacy and safety. Fertil Steril. 2011, 96, 1175-1189.
16. Conneely O, Jericevic B, DeMayo F, [et al.]. Reproductive functions of progesterone receptor. Recent Prog Horm Res. 2002, 57, 339-355.
17. Mesiano S, Welsh T. Steroid hormone control of myometrial contractility and parturition. Semin Cell Dev Biol. 2007, 18, 321-331.
18. Conneely O, Jericevic B, Lydon J. Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2003, 8, 205-214.
19. Li Q, Kannan A, DeMayo F, [et al.]. The antiprolifarative action of progesterone in uterine epithelium is mediated by Hand2. Science. 2011, 331, 912-916.
20. Scarpin K, Graham J, Mote P, [et al.]. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal. 2009, 7, e009.
21. Kastner P, Krust A, Turcotte B, [et al.]. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990, 9, 1603-1614.
22. Conneely O, Jericevic B, Lydon J, [et al.]. Reproductive functions of progesterone receptor isoforms: lessons from knock-out mice. Mol Cell Endocrinol. 2001, 179, 97-103.
23. Chabbert-Buffet N, Meduri G, Bouchard P, [et al.]. Selective progesterone receptor modulators and progesterone antagonists: mechanism of action and clinical application. Hum Reprod Update. 2005, 11, 293-307.
24. Smith C, O'Malley B. Coregulator functions: a key to understanding tissue specifity of selective receptor modulators. Endocr Rev. 2004, 25, 45-71.
25. Boonyaratanakornkit V, Edwards D. Receptor mechanism mediating non-genomic actions of sex steroids. Semin Reprod Med. 2007, 25, 139-153.
26. Philibert D. RU 38486: an original multifaced antihormone in vivo. In: Adrenal steroid antagonism. Ed. Agarwal M. Berlin: Walter de Gruyter.1984, 77-101.
27. Madauss K, Grygielko E, Deng S, [et al.]. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol. 2007, 21, 1066-1081.
28. Liu Z, Auboeuf D, Wong J, [et al.]. Coactivator/corepressor ratios modulate PR-mediated transcripction by the selective receptor modulator RU486. Proc Natl Acad Sci USA 2002, 99, 7940- 7944.
29. Hermanson O, Glass C, Rosenfeld M. Nuclear receptor coragulators: multiple modes of modification. Trends Endocrinol Metabol. 2002, 13, 55-60.
30. Gellersen B, Brosens J. Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair. J Endocrinol. 2003, 178, 357-372.
31. Madauss K, Stewart E, Williams S. The evolution of progesterone receptor ligands. Med Res Rev. 2007, 27, 374-408.
32. McPhail M. The assay of progestin. J Physiol. 1934, 83, 145-156.
33. Elger W, Bartley J, Schneider B, [et al.]. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR agonistic and antagonistic activity. Steroids. 2000, 65, 713-723.
34. Afhüppe W, Sommer A, Miller J, [et al.]. Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system. J Steroid Biochem Mol Biol. 2009, 113, 105-115.
35. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/002041/ human_med_001542.jsp&mid=WC0b01ac058001d124
36. Croxatto H, Salvatierra A, Croxatto H, [et al.]. Effects of continous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod. 1993, 8, 201-207.
37. Liu J, Garzo G, Morris S, [et al.]. Disruption of follicular maturation and delay of ovulation after administration of antiprogesterone RU486. J Clin Endocrinol Metabol. 1987, 65, 1135-1140.
38. Stratton P, Levens E, Hartog B, [et al.]. Endometrila effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertil Steril. 2009, 93, 2035-2041.
39. Banaszak S, Brudney A, Donnelly K, [et al.]. Modulation of the action of chorionic gonadotropin in the baboon (Papio anubis) uterus by progesterone receptor antagonist (ZK 137-316). Biol Reprod. 2000, 63, 820-825.
40. Petersen A, Bentin-Ley U, Ravn V, [et al.]. The antiprogesterone ORG 31710 inhibits human blastocyst-endometrial interactions in vitro. Fertil Steril. 2005, 85, (Suppl 1), 1255-1263.
41. Baird D, Thong K, Hall C, [et al.]. Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days. Hum Reprod. 1995, 10, 2270-2276.
42. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of progesterone receptor modulator VA2914 in a continous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metabol. 2007, 92, 3582-3589.
43. Fiala C, Gemzel-Danielsson K. Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception. 2006, 74, 66-86.
44. Han S, Sidell N. RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. J Clin Endocrinol Metabol. 2003, 88, 713-719.
45. Brenner R, Slayden O, Nath A, [et al.]. Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium in rhesus macaques. Contraception. 2010, 81, 336-342.
46. Gopalkrishnan K, Katkam R, Sachdeva G, [et al.]. Effects of antiprogestin onapristone on the endometrium of bonnet monkeys: morphometric and ultrastructural studies. Biol Reprod. 2003, 68, 1959-1967.
47. Zhang Z, Lundeen S, Slayden O, [et al.]. In vitro and in vivo characterization of a novel nonsteroidal, species specific progesterone receptor modulator, PRA-910. Ernst Schering Found Symo Proc. 2007,171-197.
48. Grow D Williams R, Hsiu J, [et al]. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab. 1996, 81, 1933-1939.
49. Stoeckemann K, Hegele-Hartung C, Chwalisz K. Effects of the progesterone antagonist onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats. Hum Reprod. 1995,10, 3264-3271.
50. Elger W, Ivell R, Nandy A, [et al.]. Modulation of uterine prostaglandin secretion by the selective progesterone receptor modulator (SPRM) asoprisnil, progestins, and antiprogestins in cycling and ovariectomized guinea pigs. Fertil Steril. 2004, 82, (Suppl), 316.
51. Gemzell-Danielsson K, Hamberg M. The effect of antiprogestin (RU 486) and prostaglandin synthesis inhibitor (naproxen) on uterine fluid prostaglandin F2 concentrations. Hum Reprod. 1994, 9, 1626-1630.
52. Kettel L, Murphy A, Morales A, [et al.]. Treatment of endometriosis with the antiprogesterone mifepriston (RU 486). Fertil Steril. 1996, 65, 23-28.
53. Mei L, Bao J, Tang L, [et al.]. A novel mifepriston-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies. Eur J Pharm Sci. 2010, 39, 421-425.
54. Chwalisz K, Mattia-Goldberg C, Elger W, [et al.]. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril. 2004, 82, 83-84.
55. De Vivo I, Huggins G, Hankinson S, [et al.]. A functional polymorphism in the promoter of the progesterone receptro gene associated with endometrial cancer risk. Proc Natl Acad Sci USA. 2002, 99, 12263-12268.
56. Arnett-Mansfield R, DeFazio A, Mote P, [et al.]. Subnuclear distributions of progesterone receptors A and B in normal and malignant endometrium. J Clin Endocrinol Metabol. 2004, 89, 1429-1442.
57. Akahira J, Inoue T, Suzuki T, [et al.]. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma : immunohistochemical and RT-PCR studies. Br J Cancer. 2000, 83, 1488- 1494.
58. Fujimoto J, Ichigo S, Hori M, [et al.]. Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumor Biol. 1995, 16, 254-260.
59. Ariga N, Suzuki T, Moriya T, [et al.]. Progesterone receptor A and B isoforms in the human breast and its disorders. Jpn J Cancer Res. 2001, 92, 302-308.
60. Klijn J, Setyono Han B, Foekens J. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000, 65, 825-830.
61. Rose F, Barnea E. Response of human ovarian carcinoma cell lines to antiprogestin mifepriston. Oncogene. 1996, 7, 999-1003.
62. Tieszen C, Goyeneche A, Brandhagen B, [et al.]. Antiprogestin mifepristone inhibit the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer. 2011, 27: doi: 10.1186/1471-2407-11-207
63. Brandon D, Erickson T, Keenan E, [et al.]. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab. 1995, 80, 1876-1881.
64. Englund K, Blanck A, Gustavsson I, [et al.]. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab. 1998, 83, 4092-4096.
65. Huet-Hudson Y, Chakraborty C, De S, [et al.]. Estrogen regulates the synthesis of epidermal growth factor in mouse uterine epithelial cells. Mol Endocrinol. 1990, 4, 510-523.
66. Harrison-Woolrych M, Robinson R. Fibroid growth in response to high-dose progestogen. Fertil Steril. 1995, 64, 191-192.
67. Maruo T. Progesterone and progesterone receptor modulator in uterine leiomyoma growth. Gynecol Endocrinol. 2007, 23, 186-187.
68. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz I. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005, 11, 293-307.
69. Bouchard P, Chabbert-Buffet N, Fauser B. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011, 96, 1175-1189.
70. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002041/ human_med_001542.jsp&mid=WC0b01ac058001d124
71. Donnez J, Tetyana F, Tatarchuk K, [et al.]. for the PEARL I Study Group Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery. N Engl J Med. 2012, 366, 409-420.
72. Donnez J, Tomaszewski J, Väzquez F, for the PEARL II Study Group Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids. N Engl J Med. 2012, 366, 421-432.
73. Stanowisko Zespolu Ekspertów Polskiego Towarzystwa Ginekologicznego w sprawie zastosowania selektywnych modulatorów receptora progesteronowego (SPRM) w leczeniu miesniaków macicy. Ginekol Pol. 2012, 83, 555-557.
74. Horne F, Blithe D. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update. 2007, 13, 567-580.